Osteoprotegerin/RANK/RANKL axis and atrial remodeling in mitral valvular patients with atrial fibrillation

International Journal of Cardiology

Volumn 166, Issue 3, 2013, Pages 702-708

  Cao, Hailong ^a   Li, Qingguo ^a   Li, Mingna ^b   Od, Røe ^b,c   Wu, Zhong ^a   Zhou, Qing ^a   Cao, Bin ^a   Chen, Baojun ^a   Chen, Yijiang ^b   Wang, Dongjin ^a  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Atrial fibrillation; Atrial remodeling; Osteoprotegerin; Receptor activator of nuclear factor B; Receptor activator of nuclear factor B ligand

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; BIOLOGICAL MARKER; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; BONE HOMEOSTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSING ALVEOLITIS; HEART ATRIUM FIBRILLATION; HEART ATRIUM REMODELING; HEART RIGHT ATRIUM; HOMEOSTASIS; HUMAN; HUMAN TISSUE; MALE; MITRAL VALVE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEX DIFFERENCE; SINUS RHYTHM; BIOSYNTHESIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SURGERY;

ADULT; ATRIAL FIBRILLATION; ATRIAL REMODELING; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 84891025071     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.11.099     Document Type: Article

References (35)

1. Zhang S. Atrial fibrillation in mainland China: epidemiology and current management. Heart 2009; 95: 1052-5.
2. Verheule S, Sato T, Everett T, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-β1. Circ Res 2004; 94: 1458-65.
3. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51: 802-9.
4. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15: 2-12.
5. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev 2008; 29: 403-40.
6. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. The osteoproteger-in/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006; 4: 801-11.
7. Steinmetz M, Skowasch D, Wernert N, et al. Differential profile of the OPG/RANKL/RANK-system in degenerative aortic native and bioprosthetic valves. J Heart Valve Dis 2008; 17: 187-93.
8. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-80.
9. Ndip A, Williams A, Jude EB, et al. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes 2011; 60: 2187-96.
10. Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005; 111: 3119-25.
11. Ueland T, Yndestad A, Øie E, et al. Dysregulated osteoprotegerin/RANK ligan-d/RANK axis in clinical and experimental heart failure. Circulation 2005; 111: 2461-8.
12. Schnabel RB, Larson MG, Yamamoto JF, et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol 2009; 104: 92-6.
13. Schwammenthal E, Vered Z, Agranat O, Kaplinsky E, Rabinowitz B, Feinberg MS. Impact of atrioventricular compliance on pulmonary artery pressure in mitral stenosis: an exercise echocardiographic study. Circulation 2000; 102: 2378-84.
14. Cao H, Xue L, Wu Y, et al. Natriuretic peptides and right atrial fibrosis in patients with paroxysmal versus persistent atrial fibrillation. Peptides 2010; 31: 1531-9.
15. Boldt A, Wetzel U, Lauschke J, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004; 90: 400-5.
16. Xu J, Cui G, Esmailian F, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004; 109: 363-8.
17. Grammer JB, Böhm J, Dufour A, Benz M, Lange R, Bauernschmitt R. Atrial fibrosis in heart surgery patients decreased collagen III/I ratio in postoperative atrial fibrillation. Basic Res Cardiol 2005; 100: 288-94.
18. Badenhorst D, Maseko M, Tsotetsi OJ, et al. Crosslinking influences the impact of quantitative changes in myocardial collagen on cardiac stiffness and remodelling in hypertension in rats. Cardiovasc Res 2003; 57: 632-41.
19. Li YY, Feng YQ, Kadokami T, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A 2000; 97: 12, 746-51.
20. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999; 96: 3540-5.
21. Halapas A, Zacharoulis A, Theocharis S, et al. Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction. Clin Chem Lab Med 2008; 46: 510-6.
22. Liu W, Feng W, Wang F, et al. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease. Exp Mol Pathol 2008; 84: 213-7.
23. Feng W, Li W, Liu W, Wang F, Li Y, Yan W. IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol 2009; 87: 212-8.
24. Wu KI, Schmid-Schönbein GW. Nuclear factor KappaB and matrix metalloproteinase induced receptor cleavage in the spontaneously hypertensive rat. Hypertension 2011; 57: 261-8.
25. Huang D, Wang Y, Yang C, Liao Y, Huang K. Angiotensin II promotes poly(ADP-ribosyl)ation of c-Jun/c-Fos in cardiac fibroblasts. J Mol Cell Cardiol 2009; 46: 25-32.
26. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-91.
27. Saba S, Janczewski AM, Baker LC, et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}. Am J Physiol Heart Circ Physiol 2005; 289:H1456-67.
28. Yun TJ, Tallquist MD, Aicher A, et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 2001; 166: 1482-91.
29. Mosheimer BA, Kaneider NC, Feistritzer C, Sturn DH, Wiedermann CJ. Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum 2004; 50: 2309-16.
30. Ho TY, Santora K, Chen JC, Frankshun AL, Bagnell CA. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis. Bone 2011; 48: 1346-53.
31. Sandberg WJ, Yndestad A, Øie E, et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006; 26: 857-63.
32. Bennett BJ, Scatena M, Kirk EA, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/mice. Arterioscler Thromb Vasc Biol 2006; 26: 2117-24.
33. Jurado S, Garcia-Giralt N, Díez-Pérez A, et al. Source effect of IL-1beta, PGE(2), and TGF-beta1 on the expression of OPG and RANKL in normal and osteoporotic primary human osteoblasts. J Cell Biochem 2010; 110: 304-10.
34. Koh JM, Lee YS, Byun CH, et al. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells. J Endocrinol 2005; 185: 401-13.
35. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004; 35: 1636-41.